Takeda Pharmaceutical (TAK) Operating Expenses (2017 - 2026)

Takeda Pharmaceutical's Operating Expenses history runs 10 years deep, the most recent figure standing at -$3.1 billion for Q1 2026.

• In Q1 2026, Operating Expenses rose 2.49% year-over-year to -$3.1 billion; the TTM figure through Mar 2026 stood at -$15.6 billion (changed 0.42% YoY), while the FY2026 annual figure was -$11.7 billion, up 2.93% from the prior year.
• Operating Expenses was -$3.1 billion for Q1 2026 at Takeda Pharmaceutical, down from -$3.1 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $14.3 billion in Q1 2024 to a low of -$6.6 billion in Q3 2024.
• Historically, Operating Expenses has averaged -$2.4 billion across 5 years, with a median of -$3.1 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses plunged 123.06% in 2022, then surged 560.03% in 2024.
• A 5-year view of Operating Expenses shows it stood at -$3.1 billion in 2022, then retreated by 3.09% to -$3.2 billion in 2023, then increased by 3.86% to -$3.1 billion in 2024, then advanced by 0.15% to -$3.1 billion in 2025, then decreased by 1.53% to -$3.1 billion in 2026.
• The last three Operating Expenses figures came in at -$3.1 billion (Q1 2026), -$3.1 billion (Q4 2025), and -$6.6 billion (Q3 2025), per Business Quant data.